UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
All News
Article
Article
I'd like to discuss the similarities between polymyalgia rheumatica and palindromic rheumatism. And in doing that, highlight how these similarities help us understand the relationship between polymyalgia rheumatica and rheumatoid arthritis. Perhaps not everybody watching this will be very familiar with palindromic rheumatism. It is considered uncommon, but every rheumatologist sees it in their practice.
Article
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
Could Methotrexate Work in Hand Osteoarthritis?
Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!
https://t.co/GhVB7WzJLQ https://t.co/Lt0pvm3RCW
12.3 million Americans over 50 have osteoporosis; 47 million have osteopenia. W/ OP Fx the risk of repeat Fx is highest in 1st 6 mos, yet 8% of Medicare pts w/ Fx have a diagnostic bone density scan (less in African Americans 5%) https://t.co/2mogEEk3tq https://t.co/9tjwXg0WzZ https://t.co/ruLnjm4kXr
Tuesday Nite Rheumatology webinar on the use of steroid-sparing drugs in patients with #PMR.
Featuring Panelists: Drs. David Liew, Robert Spiera, Sarah Mackie, Anisha Dua
Moderator: Dr. Sebastian Sattui
https://t.co/HDXCG1bq2m https://t.co/95vfTnXtNP
Tocilizumab Use in #GCA. In 10 yrs, 114 GCA pts started on TCZ after mean 4.5 mos & Rx for 2.3 yrs. GCA Relapse rates:
- before TCZ 0.84/PY
- on TCZ 0.28/PY (P<0.001)
- post TCZ D/C 0.64/PY
52 pts D/C TCZ after 16.8 mos & 27 (52%) relapsed after 8.4 mo https://t.co/D3INiMdC4U https://t.co/aD2rijR6xd
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/9TEUOODO1P https://t.co/5IhVmOpTCB
Anifrolumab was studied in 7 adolescents w/ resistant #DLE (discoid); given 6 monthly IV doses. All had signif decreases in skin CLASI-A scores (72%) at 1 month (P =.01), sustained at 6-mo F/U. SLEDAI-2K score also decr by 7 pts; 1 had HSV-1 reactivation https://t.co/Nc0IN1Rsao https://t.co/XeAB99YZMF
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/IeobNWcM94 https://t.co/OMbhVwFCCt
#PMR: Ageism, Pain and Drug Management
Dr. Divyani Misra, Boston, discusses ageism, pain and drug management in older adults with polymyalgia rheumatica.
https://t.co/opWAJoF8b3 https://t.co/0JUrdnGa8s
Learn about enhancing patient care in axSpA through this engaging video series, as Dr Lianne Gensler and Dr Atul Deodhar walk through the updates to the ASAS-EULAR Guidelines. https://t.co/NxGuOXPKjZ https://t.co/HdCGE3ZgpI
Fever of Unknown Origin
Featuring Dr. Sebastian Sattui (Pittsburgh)
68 yr. old with fatigue and daily fevers of 101F; what's the differential diagnosis?
https://t.co/il6EBLOp0M
#PMR https://t.co/PL5DSdRb1s
Frailty in #PMR: Why do I need to care?
https://t.co/JYbavonDWL https://t.co/aP97c6zFIH
Sleep Apnea Smart Watches
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.
https://t.co/BbBa4JaOV3 https://t.co/vcOxbP6yhQ
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation?
https://t.co/fr2y9VLSMD https://t.co/RsANcK5pbi
TONIGHT at 7pm ET! Join us for #PMR & Steroid-Sparing Therapeutics featuring panelists Drs. Robert Spiera and Sarah Mackie, and moderator Dr. Sebastian Sattui .
https://t.co/EslrRh7ArO https://t.co/3WY881eDGP
IL-6 Inhibitors in #PMR: Give early or late?
https://t.co/Hg7ZJJxaGD https://t.co/cJdnTPI3YD
AbbVie US Medical Affairs sponsored posters are now available:
Long-term Safety of a JAKi in Patients with RA With up to 6.5 Years of Exposure. https://t.co/0PQT6qExcQ https://t.co/PYbdwQeKEA
Steroids and #PMR
In this Tuesday Night Rheumatology webinar, the panel discussed the use of corticosteroids in patients with polymyalgia rheumatica. Panelists: Drs. Lindsay Lally, Richard Conway and Max Yates. Moderated by Dr. David Liew.
https://t.co/t27SldsJ9z https://t.co/8knPPLw3OE


